Y-Mabs Therapeutics
Y-mAbs is a biopharmaceutical company developing and commercializing novel radioimmunotherapy and antibody-based therapies, now part of SERB Pharmaceuticals.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Y-mAbs Therapeutics is a biopharmaceutical company focused on developing and commercializing novel radioimmunotherapy and antibody-based therapies for challenging diseases. Founded in 2015 by Thomas Gad, the company is now part of SERB Pharmaceuticals. Its first commercial product is DANYELZA® (naxitamab-gqgk).
History
Y-mAbs was founded in 2015 by Thomas Gad, who launched the company to help families access cutting-edge therapies like those used to treat his daughter with high-risk neuroblastoma. The company is now part of SERB Pharmaceuticals.
Products and positioning
DANYELZA®
First commercial product, naxitamab-gqgk, with boxed warning on serious infusion-related reactions and neurotoxicity.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/y-mabs-therapeutics · Editorial policy · How profiles are compiled